Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

On this page, you’ll find some frequently asked questions about MAYZENT®▼ (siponimod) and the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease. Click on the headings below to learn more and reveal the answers to the questions. 

Listen to Dr Emma Tallantyre (Consultant Neurologist, Cardiff University Hospital) provide an overview of the study design of the MAYZENT pivotal trial in patients with SPMS.

Learn more about the pivotal trial.

Clinical data

 
 

Listen to Dr Emma Tallantyre (Consultant Neurologist, Cardiff University Hospital) discuss the key efficacy outcomes from the MAYZENT pivotal trial in patients with SPMS.

Learn more about MAYZENT efficacy.

Efficacy

 
 

Listen to Dr Martin Duddy (Clinical Director and Consultant Neurologist, Royal Victoria Infirmary, Newcastle upon Tyne) talk about safety considerations for MAYZENT.

Learn more about MAYZENT safety.

Safety

 
 

Listen to Dr Wallace Brownlee (MS Specialist Neurologist, University College London Hospitals NHS Foundation Trust) talk about how he identifies SPMS in his clinical practice.

Learn more about SPMS.

SPMS

 
 

Hear Dr David Paling (Consultant Neurologist, The Royal Hallamshire Hospital, Sheffield) talk about how he identifies patients who are suitable candidates for MAYZENT in his clinical practice.

Learn more about identifying MAYZENT patients.

Patient profiles

 
 

Hear Dr Martin Duddy (Clinical Director and Consultant Neurologist, Royal Victoria Infirmary, Newcastle upon Tyne) discuss the commonly reported side effects of MAYZENT.

Learn more about MAYZENT safety.

Safety

 
 
  • Prior to initiation of treatment with MAYZENT, antibody-negative patients should receive the full course of varicella vaccination. Treatment with MAYZENT should not be initiated until at least 1 month after receiving the vaccine.
  • Other live-attenuated vaccines should not be given during MAYZENT treatment or for at least 4 weeks after the last dose. 
  • Vaccinations may be less effective if administered during MAYZENT treatment. Discontinuation of treatment 1 week prior to planned vaccination until 4 weeks after is recommended. When stopping MAYZENT therapy for vaccination, the possible return of disease activity should be considered.

For more information, please refer to the Summary of Product Characteristics here.

  • When switching a patient from another disease-modifying therapy, the half-life and mechanism of action should be considered with the aim to avoid additive effects while still minimising the reactivation of disease. 
  • A peripheral lymphocyte count (CBC) is recommended prior to initiating MAYZENT to ensure that immune effects of the previous therapy have resolved.
  • Treatment with MAYZENT can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.
  • Initiating treatment with MAYZENT after alemtuzumab is not recommended, unless benefits strongly outweigh the risks.

Find resources to help you switch patients to MAYZENT safely.

Resources

Prescribing information for MAYZENT (siponimod) and adverse event reporting details can be found here.

Prescribing information for GILENYA▼ (fingolimod) and adverse event reporting details can be found here.

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

Reference

  1. Novartis Pharmaceuticals UK Ltd. MAYZENT® (siponimod): Summary of Product Characteristics [online]. Available at: https://www.medicines.org.uk/emc/product/11019/smpc#gref [Accessed February 2022].
Rate this content: 
No votes yet
UK | February 2022 | 177639
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]